These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 455886)

  • 21. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction between oral propranolol and hydralazine.
    McLean AJ; Skews H; Bobik A; Dudley FJ
    Clin Pharmacol Ther; 1980 Jun; 27(6):726-32. PubMed ID: 7379440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects.
    Walle T; Walle UK; Cowart TD; Conradi EC
    Clin Pharmacol Ther; 1989 Sep; 46(3):257-63. PubMed ID: 2776391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates.
    Walle T
    Drug Metab Dispos; 1985; 13(3):279-82. PubMed ID: 2861983
    [No Abstract]   [Full Text] [Related]  

  • 25. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
    Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
    J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of individual differences in gastric emptying to variability in plasma propranolol concentrations.
    Castleden CM; George CF; Short MD
    Br J Clin Pharmacol; 1978 Feb; 5(2):121-2. PubMed ID: 619945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 29. Dose-dependent presystemic elimination of propranolol due to hepatic first-pass metabolism in rats.
    Iwamoto K; Watanabe J
    J Pharm Pharmacol; 1985 Nov; 37(11):826-8. PubMed ID: 2867168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereoselective ring oxidation of propranolol in man.
    Walle T; Walle UK; Wilson MJ; Fagan TC; Gaffney TE
    Br J Clin Pharmacol; 1984 Nov; 18(5):741-8. PubMed ID: 6508983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats.
    Terao N; Shen DD
    J Pharmacokinet Biopharm; 1984 Oct; 12(5):479-93. PubMed ID: 6520744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propranolol absorption in untreated coeliac disease.
    Sandle GI; Ward A; Rawlins MD; Record CO
    Clin Sci (Lond); 1982 Jul; 63(1):81-5. PubMed ID: 7083769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between plasma propranolol concentration and dose in young, healthy volunteers.
    Dey M; Brisson J; Davis G; Enever R; Pray K; Zaim B; Dvornik D
    Biopharm Drug Dispos; 1986; 7(2):103-11. PubMed ID: 3708118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis.
    Olanoff LS; Walle T; Cowart TD; Walle UK; Oexmann MJ; Conradi EC
    Clin Pharmacol Ther; 1986 Oct; 40(4):408-14. PubMed ID: 3757404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-dependent disposition of oral propranolol in normal subjects.
    Mackichan JJ; Pyszczynski DR; Jusko WJ
    Biopharm Drug Dispos; 1980; 1(4):159-66. PubMed ID: 7448344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
    Byrne AJ; McNeil JJ; Harrison PM; Louis W; Tonkin AM; McLean AJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):45S-50S. PubMed ID: 6743474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
    Wagner JG
    Clin Pharmacol Ther; 1985 May; 37(5):481-7. PubMed ID: 3987171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma.
    Silber B; Riegelman S
    J Pharmacol Exp Ther; 1980 Dec; 215(3):643-8. PubMed ID: 7441523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates.
    Walle T; Wilson MJ; Walle UK; Bai SA
    Drug Metab Dispos; 1983; 11(6):544-9. PubMed ID: 6140137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of propoxyphene and propranolol in children.
    Wilson JT; Atwood GF; Shand DG
    Clin Pharmacol Ther; 1976 Mar; 19(3):264-70. PubMed ID: 1261164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.